There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > All Other Proteins > CD19 > CD9-H5251

Human CD19 (20-291) Protein, Fc Tag, low endotoxin (Super affinity, MALS verified) DMF Filed

  • Synonym
  • Source
    Human CD19 (20-291), Fc Tag (CD9-H5251) is expressed from human 293 cells (HEK293). It contains AA Pro 20 - Lys 291 (Accession # P15391-1).
    Predicted N-terminus: Pro 20
  • Molecular Characterization
    Online(Pro 20 - Lys 291) P15391-1

    This protein carries a human IgG1 Fc tag at the C-terminus.

    The protein has a calculated MW of 56.6 kDa. The protein migrates as 70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin
    Less than 0.1 EU per μg by the LAL method.
  • Purity

    >90% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
Human CD19 (20-291), Fc Tag (Cat. No. CD9-H5251) SDS-PAGE gel

Human CD19 (20-291), Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

Human CD19 (20-291), Fc Tag (Cat. No. ) MALS images

The purity of Human CD19 (20-291), Fc Tag (Cat. No. CD9-H5251) was more than 95% and the molecular weight of this protein is around 140-160 kDa verified by SEC-MALS.

Human CD19 (20-291), Fc TagHuman CD19 (20-291), Fc Tag (Cat. No. CD9-H5251) ELISA bioactivity

Immobilized FMC63 (Mouse IgG2a) at 1 μg/mL (100 μL/well) can bind Human CD19 (20-291), Fc Tag (Cat. No. CD9-H5251) with a linear range of 1-31 ng/mL (QC tested).

Human CD19 (20-291), Fc TagHuman CD19 (20-291), Fc Tag (Cat. No. CD9-H5251) ELISA bioactivity

Immobilized Human CD19 (20-291), Fc Tag (Cat. No. CD9-H5251) at 5 μg/mL (100 μL/well) can bind FMC63 (Mouse IgG2a) with a linear range of 0.6-5 ng/mL (Routinely tested).


Human CD19 (20-291), Fc Tag (Cat. No. CD9-H5251) captured on CM5 chip via Anti-Human lgG Fc antibodies surface, can bind FMC63 MAb (Mouse lgG2a) with an affinity constant of 0.17 nM as determined in a SPR assay (Biacore T200) (Routinely tested).


Loaded Human CD19 (20-291), Fc Tag (Cat. No. CD9-H5251) on AHC Biosensor, can bind FMC63 MAb (Mouse lgG2a) with an affinity constant of 0.483 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Evaluation of CAR expression
FACS Analysis of anti-CD19 CAR Expression
Evaluation of CAR expression

293 cells were transfected with FMC63-scFv and RFP tag. 2e5 of the cells were first stained with B. Human CD19 (20-291), Fc Tag (Cat. No. CD9-H5251, 3 µg/mL) and C. Human Fc Tag Protein Control, followed by FITC-conjugated Anti-human IgG Fc Antibody. A. Non-transfected 293 cells and C. Human Fc Tag Protein Control were used as negative control. RFP was used to evaluate CAR (anti-CD19-scFv) expression and FITC was used to evaluate the binding activity of Human CD19 (20-291), Fc Tag (Cat. No. CD9-H5251).

  • Citations
  • Background
    B-lymphocyte antigen CD19 is also known as CD19 (Cluster of Differentiation 19), is a single-pass type I  membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. It primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2.
  • Clinical and Translational Updates
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)

Order Details

Price(USD) : $410.00

Price(USD) : $2600.00

Promotion & Exhibitions

Drug Development Status

  • Number of Launched Drugs:6 Details
  • Number of Drugs in Clinical Trials:159 Details
  • Latest Research Phase:Phase 3 Clinical

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.